Paris-based deeptech startup Spore.Bio has raised $23 million in a Series A funding round led by Singular, with participation from Point72 Ventures, 1st Kind Ventures, Station F, and Lord David Prior. Returning investors LocalGlobe, No Label Ventures, and Famille C also backed the round, marking a significant milestone for the company. This new funding follows Spore.Bio’s €8 million ($8.3 million) pre-seed round last year and underscores the strong market demand for its innovative microbiology testing technology.

Transforming an Industry with AI-Powered Solutions

Microbiology testing plays a crucial role in food, pharmaceutical, and cosmetics manufacturing, where contamination incidents can result in severe financial and reputational damage. Traditional testing methods rely on laboratory-based petri-dish cultivation, a slow process that takes several days to deliver results. Spore.Bio has developed an AI-powered system that analyzes bacterial presence in seconds, offering an unprecedented level of speed and efficiency in quality control.

Strong Market Demand and Rapid Growth

Over the past year, Spore.Bio has expanded from a team of 10 to 30 scientists dedicated to advancing its breakthrough technology. The company has already signed commercial agreements covering 200 factories and has established a waitlist due to high demand. With bacterial outbreaks on the rise, Spore.Bio’s solution is gaining traction as an essential tool for companies seeking to improve safety and compliance in manufacturing environments.

How the Technology Works

Unlike conventional methods that require samples to be sent to specialized labs, Spore.Bio employs a cutting-edge spectral analysis technique. By directing light at specific wavelengths onto a sample, the system captures its spectral signature and analyzes it using a pre-trained deep learning algorithm. This approach allows for real-time detection of bacterial contamination without the need for lengthy incubation periods, significantly accelerating the decision-making process for manufacturers.

Strategic Vision and Future Plans

With this latest round of funding, Spore.Bio is poised to scale its operations and deploy its systems across multiple industries. The company plans to double its workforce and work closely with the Institut Pasteur to build the world’s largest microbial dataset. By leveraging AI and data-driven insights, Spore.Bio aims to set a new standard in microbiology testing and drive widespread adoption of its technology.

Investor Confidence and Industry Impact

Investors have expressed strong confidence in Spore.Bio’s potential to disrupt the industry, citing the company’s rapid progress and real-world impact. Having backed the startup in earlier rounds, key investors emphasized the importance of supporting deeptech innovations that bridge scientific breakthroughs with practical applications. As the company continues its expansion, its AI-driven approach is expected to transform quality control processes across various sectors, reducing risks and enhancing public health safety.

Spore.Bio’s success highlights the growing importance of AI-driven solutions in tackling long-standing challenges in microbiology testing. By significantly reducing the time needed for bacterial detection, the company is helping industries mitigate risks and improve operational efficiency. As it scales its technology and builds its dataset, Based on the title and subtitle, create an SEO-optimized meta description, no longer than 130 characters. is well-positioned to lead a new era of rapid and accurate microbial analysis.